Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease

被引：0
|
作者：
Sunil Taneja
Ajay Duseja
Arka De
Manu Mehta
Raja Ramachandran
Vivek Kumar
Harbir Singh Kohli
Krishan Lal Gupta
Radha Krishan Dhiman
Yogesh Chawla
机构：
[1] Postgraduate Institute of Medical Education and Research,Department of Hepatology
[2] Postgraduate Institute of Medical Education and Research,Department of Nephrology
来源：
Digestive Diseases and Sciences | 2018年 / 63卷
关键词：
Chronic hepatitis C; Sofosbuvir; Daclatasvir; Chronic kidney disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1334 / 1340
页数：6
相关论文
共 50 条
  • [41] Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
    Cavalcante, Ludimila
    Amin, Asim
    Lutzky, Jose
    CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 47 - 50
  • [42] Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease
    Chuang, Wan-Long
    Hu, Tsung-Hui
    Buggisch, Peter
    Moreno, Christophe
    Su, Wei-Wen
    Biancone, Luigi
    Camargo, Marianne
    Hyland, Robert
    Lu, Sophia
    Kirby, Brian J.
    Dvory-Sobol, Hadas
    Osinusi, Anu
    Gaggar, Anuj
    Peng, Cheng-Yuan
    Liu, Chen-Hua
    Sise, Meghan E.
    Mangia, Alessandra
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (09): : 1924 - 1928
  • [43] Safe administration of temozolomide in end-stage renal disease patients
    Hundal, Jasmin
    Singh, Aditi
    Pereira, Megan K.
    Vredenburg, James
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 992 - 995
  • [44] Full-Dose Peginterferon Alfa-2a and Low-Dose Ribavirin Treatment of Genotypes 1 and 4 Chronic Hepatitis C Patients With End-Stage Renal Disease Reply
    Peck-Radosavljevic, Markus
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (11) : 1005 - 1005
  • [45] Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease
    Sise, Meghan E.
    McQuaid, Thomas
    Martin, Paul
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 (12) : 2327 - 2334
  • [46] Sofosbuvir-Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation
    Gaur, Nisha
    Malhotra, Vinay
    Agrawal, Dhananjai
    Singh, Shailendra K.
    Beniwal, Pankaj
    Sharma, Sanjeev
    Jhorawat, Rajesh
    Rathore, Vinay
    Joshi, Harshal
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2020, 10 (03) : 189 - 193
  • [47] The combination of sofosbuvir and daclatasvir is well tolerated and extremely effective in treating patients with hepatitis C with severe renal impairment including hemodialysis patinets
    Merat, Shahin
    Sharifi, Amir-Houshang
    Shayesteh, Ali Akbar
    Minakari, Mohammad
    Fattahi, Mohammad Reza
    Moini, Maryam
    Roozbeh, Fatemeh
    Mansour-Ghanaei, Fariborz
    Afshar, Behrooz
    Mokhtare, Marjan
    Amiriani, Taghi
    Sofian, Masomeh
    Somi, Mohammad-Hossein
    Agah, Shahram
    Maleki, Iradj
    Latifnia, Maryam
    Hormati, Ahmad
    Khoshnia, Masoud
    Sohrabi, Masoud
    Malekzadeh, Reza
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E233 - E233
  • [48] Hepatitis C infection and the patient with end-stage renal disease
    Fabrizi, F
    Poordad, FF
    Martin, P
    HEPATOLOGY, 2002, 36 (01) : 3 - 10
  • [49] Treatment of hepatitis C virus infection in patients with end-stage renal disease
    Liu, Chen-Hua
    Kao, Jia-Horng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (02) : 228 - 239
  • [50] Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
    Pockros, Paul J.
    Reddy, K. Rajender
    Mantry, Parvez S.
    Cohen, Eric
    Bennett, Michael
    Sulkowski, Mark S.
    Bernstein, David E.
    Cohen, Daniel E.
    Shulman, Nancy S.
    Wang, Deli
    Khatri, Amit
    Abunimeh, Manal
    Podsadecki, Thomas
    Lawitz, Eric
    GASTROENTEROLOGY, 2016, 150 (07) : 1590 - 1598
12345